NUVB — Nuvation Bio Inc.

Summary of Nuvation Bio's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $41.9 million for Q4 2025; $62.9 million for the full year.
• IBTROZI Revenue: $15.7 million in Q4; $24.7 million for the full year.
• Cash Position: Ended 2025 with $529.2 million in cash, cash equivalents, and marketable securities, bolstered by a $60 million upfront payment from Eisai.
• R&D Expenses: $34.3 million for Q4; $115.1 million for the year.
• SG&A Expenses: $40.3 million for Q4; $151.6 million for the year.

2. Strategic Updates and Business Highlights

• IBTROZI Launch: Achieved FDA approval in June 2025 for ROS1-positive non-small cell lung cancer (NSCLC). By year-end, 432 patients had started treatment, with 216 new patients in Q4.
• Market Penetration: IBTROZI is being prescribed at a rate 6x faster than previous ROS1 TKIs. The company is focusing on increasing its prescriber base and targeting newly diagnosed patients.
• Partnerships: Strategic partnership with Eisai for European markets, with potential milestone payments and royalties.
• Safusidenib Development: Progressing with a Phase III study for IDH1 mutant glioma, with a focus on high-risk patients and a separate cohort for grade 3 oligodendroglioma.

3. Forward Guidance and Outlook

• 2026 Revenue Expectations: No specific revenue guidance provided, but management is optimistic about meeting consensus estimates of $150 million based on patient uptake trends.
• Patient Start Trends: Anticipated growth in first-line patient starts, which are expected to drive revenue growth as the patient mix shifts from late-line to first-line treatments.
• Clinical Data Presentations: Plans to present additional long-term IBTROZI data at medical conferences in 2026.

4. Challenges and Points of Concern

• Patient Discontinuation Rates: High discontinuation rates (75%) observed in late-line patients, which could impact revenue as these patients do not remain on therapy long-term.
• Market Competition: Potential competition from new entrants in the second-line setting later in 2026, which could affect IBTROZI's market share.
• Visibility on Patient Mix: Limited visibility into the characteristics of patients starting treatment, particularly in the first-line setting, complicates revenue forecasting.

5. Notable Q&A Insights

• Patient Uptake: Management expressed confidence in the trajectory of patient starts, with expectations for growth in first-line use as the company captures more TKI-naive patients.
• Regulatory Engagement: The company is actively engaging with regulators to enhance IBTROZI's positioning in treatment guidelines.
• Safusidenib Enrollment: Management is optimistic about enrollment in the Phase III study for safusidenib, given the significant unmet need in the high-grade glioma population.
• Market Dynamics: The team emphasized the importance of educating healthcare providers about the benefits of IBTROZI, particularly its CNS penetration, which differentiates it from crizotinib.

Overall, Nuvation Bio's Q4 2025 earnings call highlighted a strong launch for IBTROZI, significant revenue potential, and ongoing development of safusidenib, while also acknowledging challenges related to patient retention and competitive pressures.